RT Journal Article
SR Electronic
T1 Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 697
OP 700
DO 10.3899/jrheum.170150
VO 44
IS 5
A1 Alexis Ogdie
A1 Maarten de Wit
A1 Kristina Callis Duffin
A1 Willemina Campbell
A1 Jeffrey Chau
A1 Laura C. Coates
A1 Lihi Eder
A1 Musaab Elmamoun
A1 Oliver FitzGerald
A1 Dafna D. Gladman
A1 Niti Goel
A1 Jana James
A1 Umut Kalyoncu
A1 John Latella
A1 Chris Lindsay
A1 Philip J. Mease
A1 Denis O’Sullivan
A1 Ingrid Steinkoenig
A1 Vibeke Strand
A1 William Tillett
A1 Ana-Maria Orbai
YR 2017
UL http://www.jrheum.org/content/44/5/697.abstract
AB The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group recently published the updated 2016 psoriatic arthritis (PsA) core domain set, a set of disease features that should be measured in all clinical trials. At the GRAPPA annual meeting in July 2016, the PsA working group presented the updated PsA core domain set endorsed by 90% of participants at OMERACT in May 2016 and drafted a roadmap for the development of the PsA core outcome measurement set. In this manuscript, we review the development process of the PsA core domain set and the ongoing and proposed work streams for development of a PsA core measurement set.